KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Alnylam Pharmaceuticals' Accumulated Expenses rose 2192.85% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2192.85%. This contributed to the annual value of $793.7 million for FY2024, which is 1131.52% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Accumulated Expenses stood at $1.2 billion, which was up 2192.85% from $919.0 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Accumulated Expenses registered a high of $1.2 billion during Q3 2025, and its lowest value of $280.5 million during Q1 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Accumulated Expenses had a median value of $598.5 million in 2023 and averaged $620.8 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Accumulated Expenses skyrocketed by 6155.76% in 2021 and then surged by 75.84% in 2025.
  • Alnylam Pharmaceuticals' Accumulated Expenses (Quarter) stood at $395.2 million in 2021, then skyrocketed by 38.03% to $545.5 million in 2022, then skyrocketed by 30.72% to $713.0 million in 2023, then grew by 11.32% to $793.7 million in 2024, then surged by 45.35% to $1.2 billion in 2025.
  • Its Accumulated Expenses stands at $1.2 billion for Q3 2025, versus $919.0 million for Q2 2025 and $704.2 million for Q1 2025.